The Journal of antimicrobial chemotherapy, 39(1), 35-43 (1997-01-01)
The in-vitro activity of faropenem, a novel oral penem, was studied in comparison with other beta-lactam antimicrobials against 711 recent clinical isolates including Gram-negative, Gram-positive and anaerobic bacteria. MIC data showed that faropenem was active against most members of the
Antimicrobial agents and chemotherapy, 38(9), 1974-1979 (1994-09-01)
The antibacterial activity of SY5555, a new oral penem antibiotic, was compared with those of cefaclor, cefixime, and cefteram. SY5555 was more active than the comparison agents against methicillin-susceptible Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Citrobacter freundii, Enterobacter
Novel carbon-carbon bond cleavage reaction of penem antibiotic by class C beta-lactamases.
R Tanaka et al.
The Journal of antibiotics, 47(8), 945-948 (1994-08-01)
The Japanese journal of antibiotics, 48(2), 220-228 (1995-02-01)
SY5555 in dry syrup (powder which is dissolved before use) or tablet form was given orally to 21 children with acute bacterial infections including 4 with acute pharyngitis, 5 with acute tonsillitis, 7 with acute bronchitis, 2 with acute gastroenteritis
Antimicrobial agents and chemotherapy, 39(7), 1591-1595 (1995-07-01)
The in vitro activity of WY-49605 (SUN5555) (WY) was compared with those of cefaclor, cefixime, and amoxicillin-clavulanic acid against 2,958 consecutive clinical isolates from five medical centers and 402 respiratory pathogens from 18 other facilities. Most members of the family
